Zavesca — CareFirst (Caremark)
Niemann-Pick disease, type C
Initial criteria
- Diagnosis was confirmed by genetic testing results showing mutations in NPC1 or NPC2 genes
Reauthorization criteria
- Member meets the criteria for initial approval
- Member is not experiencing an inadequate response or any intolerable adverse events from therapy
Approval duration
12 months